Mydecine Innovations Group Inc.
MYCOF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | -$40 | $0 | $0 | -$2,661 |
| G&A Expenses | -$73 | $236 | $314 | $631 |
| SG&A Expenses | -$73 | $236 | $314 | $631 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $5 | $36 | $60 | $1 |
| Operating Expenses | -$108 | $272 | $374 | -$2,028 |
| Operating Income | $77 | -$272 | -$374 | $2,028 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$24 | $259 | $75 | $495 |
| Pre-Tax Income | $53 | -$13 | -$299 | $2,524 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $53 | -$13 | -$299 | $2,524 |
| % Margin | – | – | – | – |
| EPS | 0.043 | -0 | -0.005 | 0.041 |
| % Growth | 21,450% | 95.8% | -111.7% | – |
| EPS Diluted | 0.043 | -0 | -0.005 | 0.041 |
| Weighted Avg Shares Out | 1,235 | 61,755 | 61,755 | 61,755 |
| Weighted Avg Shares Out Dil | 1,235 | 61,755 | 61,755 | 61,755 |
| Supplemental Information | – | – | – | – |
| Interest Income | $89 | $0 | $0 | $0 |
| Interest Expense | $0 | $140 | $141 | $346 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $53 | $128 | -$158 | $2,869 |
| % Margin | – | – | – | – |